IFNG and precursor B-cell acute lymphoblastic leukemia: As the delivery of IFN‐γ by gene therapy showed promising effects on the immune microenvironment at an early time‐point when the leukemic burden was limited, but loss of efficacy on day 17, we next tested whether combination therapies were able to enhance the effectiveness of IFN‐γ gene therapy in controlling the weakly immunogenic, parental B‐ALL.